TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2012 - 2025)

TherapeuticsMD has reported Asset Writedowns and Impairment for 14 years, with the latest figure at $1.3 million in Q1 2025.

• For the quarter ending Q1 2025, Asset Writedowns and Impairment changed N/A year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2025 stood at $1.3 million (changed N/A YoY), and the FY2024 full-year result was $1.3 million, changed N/A from the prior year.
• Asset Writedowns and Impairment for Q1 2025 stood at $1.3 million, up from $7000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $1.3 million in Q1 2025, with the low at -$540000.0 in Q4 2021.
• Historically, Asset Writedowns and Impairment has averaged $207666.7 across 5 years, with a median of $215000.0 in 2021.
• The largest YoY upside for Asset Writedowns and Impairment was 462.08% in 2021 against a maximum downside of 208.0% in 2021.
• TherapeuticsMD's Asset Writedowns and Impairment stood at -$540000.0 in 2021, then surged by 149.63% to $268000.0 in 2022, then tumbled by 77.99% to $59000.0 in 2023, then plunged by 88.14% to $7000.0 in 2024, then jumped by 17914.29% to $1.3 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $1.3 million (Q1 2025), $7000.0 (Q4 2024), and $59000.0 (Q1 2023), per Business Quant data.